Date: 2012-08-24
Type of information: Private placement
Company: Wilex (Germany)
Investors: UCB Pharma (Belgium) - dievini Hopp BioTech (Germany) - other existing shareholders
Amount: € 23.9 million
Funding type: private placement
Planned used: The funds will be used to finance ongoing and planned clinical studies as well as future growth.
Others: * On August 24, 2012, Wilex has resolved with the approval of the Supervisory Board to set the final number of shares from the combined capital increase (against cash or contributions in kind) at 6,460,544 new no par value bearer shares. The subscription and/or purchase price was € 3.70 per share.
As contribution in kind, the company’s shareholder dievini Hopp BioTech holding GmbH & Co. KG, Walldorf, Germany, (dievini) converted its existing loan granted to Wilex (plus interest) amounting to approximately € 7.77 million to 2,100,337 new shares (32.5% of the total volume of the capital increase) by exercising subscription rights. As planned, this will repay the loan from dievini and significantly reduce Wilex financial liabilities without adversely affecting cash reserves.
The cash rights issue involved existing shareholders exercising the remaining subscription rights and using the oversubscription option to acquire 1,682,910 new shares (26.1%). All oversubscription orders were fulfilled. In addition, 2,677,297 new shares (41.4%) were subscribed in private placements after the subscription period. The shareholders dievini and affiliated companies along with UCB Pharma S.A. participated in the cash capital increase as announced. Overall, 95.5% of the maximum possible volume was utilised.
Landesbank Baden-Württemberg, Stuttgart, (LBBW) was the sole lead manager and bookrunner of the transaction.
Wilex will receive gross proceeds of around € 16.1 million from the cash portion of the transaction, which the company will use to finance ongoing and planned clinical studies as well as future growth. Overall, the capital measure will improve the Company’s equity base by € 23.9 million.
Therapeutic area: Cancer - Oncology
